Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma.

Autor:	Al-Aloosi M; SEngine Precision Medicine, Seattle, WA, United States., Prechtl AM; SEngine Precision Medicine, Seattle, WA, United States., Chatterjee P; SEngine Precision Medicine, Seattle, WA, United States., Bernard B; SEngine Precision Medicine, Seattle, WA, United States.; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, United States., Kemp CJ; Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, United States., Rosati R; SEngine Precision Medicine, Seattle, WA, United States., Diaz RL; SEngine Precision Medicine, Seattle, WA, United States., Appleyard LR; SEngine Precision Medicine, Seattle, WA, United States., Pereira S; SEngine Precision Medicine, Seattle, WA, United States., Rajewski A; SEngine Precision Medicine, Seattle, WA, United States., McDonald A; Private Health Management, Los Angeles, CA, United States., Gordon EJ; Private Health Management, Los Angeles, CA, United States., Grandori C; SEngine Precision Medicine, Seattle, WA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2024 Jan 04; Vol. 13, pp. 1267650. Date of Electronic Publication: 2024 Jan 04 (Print Publication: 2023).
DOI:	10.3389/fonc.2023.1267650
Abstrakt:	Patients presenting with stage 4 ovarian carcinoma, including low-grade serous disease, have a poor prognosis. Although platinum-based therapies can offer some response, these therapies are associated with many side effects, and treatment resistance often develops. Toxic side effects along with disease progression render patients unable to receive additional lines of treatment and limit their options to hospice or palliative care. In this case report, we describe a patient with an unusual case of metastatic low-grade serous ovarian cancer with some features of high-grade disease who had received four previous lines of treatment and was suffering from atelectasis, pulmonary embolism, and hydronephrosis. A CLIA-certified drug sensitivity assay of an organoid culture derived from the patient's tumor (PARIS ® test) identified several therapeutic options, including the combination of fulvestrant with everolimus. On this treatment regimen, the patient experienced 7 months of stable disease and survived nearly 11 months before succumbing to her disease. This case emphasizes the clinical utility of ex vivo drug testing as a new functional precision medicine approach to identify, in real-time, personalized treatment options for patients, especially those who are not benefiting from standard of care treatments. Competing Interests: Authors MA-A, AP, PC, RR, RD, LA, SP, BB, AR, and CG are or were employed by SEngine Precision Medicine and received stock options from the company. Authors AM and EG are employed by Private Health Management. Author CK is a founder and has ownership in SEngine Precision Medicine. (Copyright © 2024 Al-Aloosi, Prechtl, Chatterjee, Bernard, Kemp, Rosati, Diaz, Appleyard, Pereira, Rajewski, McDonald, Gordon and Grandori.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu